Non-tumour Bone Marrow Lymphocytes Correlate with Improved Overall Survival in Childhood Acute Lymphoblastic Leukaemia by Edwin, C et al.
Received: 30October 2015 Revised: 12May 2016 Accepted: 14May 2016 Published on: 27 June 2016
DOI: 10.1002/pbc.26093
Pediatric
Blood &
Cancer The American Society ofPediatric Hematology/Oncology
B R I E F R E PORT
Non-tumour bonemarrow lymphocytes correlate with
improved overall survival in childhood acute lymphoblastic
leukaemia
Claire Edwin1 JoanneDean2 Laura Bonnett3 Kate Phillips1 Russell Keenan4
1Department ofWomen’s andChildren’sHealth,
Institute of TranslationalMedicine, University of
Liverpool, Liverpool, UK
2Department ofHaematology, AlderHeyChil-
dren’sNHSFoundation Trust, EatonRoad,
Liverpool, UK
3Department of Biostatistics, Institute of Trans-
lationalMedicine, University of Liverpool, UK
4Department ofHaematology andOncology,
AlderHeyChildren’sNHSFoundation Trust,
EatonRoad, Liverpool, UK
Correspondence
RussellKeenan,DepartmentofHaematology
andOncology,AlderHeyChildren’sNHSFoun-
dationTrust, EatonRoad, Liverpool L122AP,
UK.
Email: russell.keenan@alderhey.nhs.uk
Grant sponsor:WolfsonFoundation Interca-
latedAward (toCE);Grant sponsor:AlderHey
Children’sCharity LeukaemiaResearchFund (to
RK).
Abstract
Composition of tumour immune cell infiltrates correlates with response to treatment and over-
all survival (OS) in several cancer settings. We retrospectively examined immune cells present
in diagnostic bone marrow aspirates from paediatric patients with B-cell acute lymphoblastic
leukaemia.Our analysis identified a sub-group (∼30%of patients) with>2.37%CD20 and>6.05%
CD7 expression, which had 100% OS, and a sub-group (∼30% of patients) with ≤2.37% CD20
and ≤6.05% CD7 expression at increased risk of treatment failure (66.7% OS, P < 0.05). Immune
cell infiltrate at diagnosis may predict treatment response and could provide a means to enhance
immediate treatment risk stratification.
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1 INTRODUCTION
Conventional chemotherapeutic regimens cure a significant propor-
tion of paediatric patients with B-cell acute lymphoblastic leukaemia
(B-ALL). Improvements in survival rates observed over recent decades
can be attributed to the introduction of efficient testing for min-
imal residual disease during treatment and new combinations of
chemotherapeutics. However, considerable adverse effects are associ-
ated with regimens used to treat paediatric B-ALL. Strategies to iden-
tify patients in whom lower dose treatment would be clinically effec-
tive or treatment intensification would enhance survival, represent
attractive avenues to reduce long-term cytotoxicity and/or enhance
overall survival (OS).
Recent advances in our understanding of tumour immunology
suggest that an individual’s immune response, pre-therapy against
their own tumour, significantly influences disease progression.1 Sev-
eral parameters associated with the composition of immune infiltrate
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in solid tumours have been shown to correlate with prognosis, and
in some instances, to predict patient survival more accurately than
any other parameter.2,3 In B-ALL, two recent reports examining
the immunological composition of bone marrow (BM) at diagnosis
demonstrate correlation between CD4+ (where CD is cluster of
differentiation) T lymphocytes and favourable early response in pae-
diatric patients 4 and CD8+ T lymphocytes and improved OS in adult
patients.5 In this study, we examined the composition at diagnosis
of non-malignant lymphocytes in the BM of paediatric patients with
B-ALL. We aimed to identify whether non-malignant lymphocytes
routinely measured in BM aspirate by flow cytometry are associated
with OS.
2 METHODS AND RESULTS
We reviewed the medical records of 153 children diagnosed with
ALL at Alder Hey Children’s Hospital, Liverpool, between 2002 and
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TABLE 1 Patient characteristics
Study cohort, n= 55 Total patients, n= 153
Median age in years, n (IQR) 5.0 (2.5–7.5) 4.0 (1.5–6.5)
Male gender, n (%) 30 (54.5) 83 (54.2)
Age groups
<10 years, n (%) 44 (80.0) 125 (81.7)
≥10 years, n (%) 11 (20.0) 28 (18.3)
WCC at diagnosis
<50× 109 l−1, n (%) 46 (83.6) 129 (84.3)
≥50× 109 l−1, n (%) 9 (16.4) 24 (15.7)
Initial treatment protocol
Regimen A (low risk), n (%) 36 (65.5) 103 (67.3)
Regimen B (high risk), n (%) 19 (34.5) 50 (32.7)
IQR, inter-quartile range;WCC, white cell count.
2009 in accordance with NHS Health Research Authority and Royal
College of Pathologists’ guidelines. All patients had been treated in
accordance with UKALL 97/99 or UKALL 2003 trial protocol. In 55
cases, flow cytometry data from clinical diagnostic BM aspirate could
be recovered in List Mode data format and re-analysed to enumerate
data related to the non-tumour cells present. All 55 patients analysed
were diagnosed with common ALL (de novo precursor B-ALL), patient
characteristics are shown in Table 1. Patients with Philadelphia chro-
mosome positive B-ALL, common ALL with aberrant CD20 tumour
expression or Down syndrome were excluded from this study. There
were eight deaths and the remaining 47 patients were alive andwell at
the time of last follow-up, although four had experienced relapse, but
were treated successfully with salvage chemotherapy.
We assessed the measured relative frequency values of CD
markers in diagnostic BM aspirate between survivors and non-
survivors. Tumour lymphocytes (CD19+, CD10+) and non-malignant
B-lymphocytes (CD19+, CD10−) were equivalent between study
groups; however, an increased relative frequency of the mature
B-lymphocyte marker, CD20, was observed in survivors (P = 0.0295;
Fig. 1A). T lineage cells (CD2+) were equivalent between study groups;
however, an increased relative frequency of the mature T-lymphocyte
and natural killer (NK) cell marker, CD7, was observed in survivors
(P = 0.0447; Fig. 1B). Following associated receiver operating charac-
teristic analysis, cut-offs of 2.37% CD20 expression (sensitivity 88%,
specificity 56%) and6.05%CD7expression (sensitivity 88%, specificity
53%) were selected to differentiate between patients with high and
low expression.
Comparing patients with high CD20 expression (>2.37%; n =
28) to the patients with lower expression (≤2.37%; n = 27), we
observed significantly increased OS of 96.4% compared to 74.1%
(P = 0.030; Fig. 1C), and improved leukaemia-free survival (LFS) of
92.9% compared to 66.7% (P = 0.024; Fig. 1D). In a similar anal-
ysis of CD7, we observed increased OS of 96.0% in patients with
high CD7 expression (>6.05%; n = 25) compared to 76.7% in the
patients with low expression (≤6.05%; n = 30; P = 0.041; Fig. 1E),
although no improvement in LFS was noted (Fig. 1F). Combining these
factors, we observed that patients with high CD20 expression and
high CD7 expression (n = 16) had 100% OS compared to 66.7%
in patients with low expression of both markers (n = 18; Fig. 1G;
P = 0.013), and improved LFS of 87.5% compared to 61.1% (P= 0.045;
Fig. 1H).
3 DISCUSSION
Our retrospective analysis of CD marker expression in diagnostic BM
aspirates identified a group of patients (16 out of 55) who could be
characterised at diagnosis according to high CD20 and high CD7
expression,whoexperienced100%OS.Conversely, patientswhocould
be characterised according to low CD20 and low CD7 expression (18
outof 55) experienced significantly reducedOS, 66.7%, suggesting that
the BM immune infiltrate at diagnosis is indicative of, or can be corre-
lated with, their response to treatment.
An increasing body of literature exists linking immune system
parameters at diagnosis with prognosis in cancer patients.1 Immune
cell infiltrate may represent an ongoing but ineffective antitumour
immune response, or a collection of tumour-promoting cells recruited
into the tumour micro-environment. This so-called ‘tumour immune
contexture’ may be relevant to understanding a patients’ response
to treatment,6 and the induction of an antitumour immune response
has the potential to enhance survival prospects. Lymphocytes per-
form immune surveillance and may recognise malignant cells as
immunogenic.7 CD20 is expressed on mature B cells with the excep-
tion of terminally differentiated plasmablasts or plasma cells. Resting
B cells express surface immunoglobulin (Ig) as a receptor;8 antigen
engagement of surface Ig can activate B cells and leads to internali-
sation of antigen and presentation of peptides complexed with major
histocompatibility complex class II at the cell surface for interaction
with CD4+ T cells.8,9 Lymphocytes are also immune effector cells, and
may mediate tumour cell death through granule exocytosis or death
receptor signalling, cytotoxic T cells andNKs are key effectors in these
mechanisms. Interaction between B and T cells serves to augment
adaptive immune responses through cross-priming of T cells, recip-
rocal enhancement of activation signalling in each cell type and the
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F IGURE 1 CD20+ lymphocyteswere increased in survivors compared to non-survivors (A), CD7+ lymphocyteswere increased in survivors com-
pared to non-survivors (B). Enhanced OS (C) and LFS (D) was observed in paediatric patients with B-ALL having >2.37% CD20+ lymphocytes.
Enhanced OS (E) but not LFS (F) was observed in paediatric patients with B-ALL having >6.05% CD7+ lymphocytes. 100% OS was observed in
patients having>2.37%CD20+ and>6.05%CD7+ lymphocytes (G). 87.5% LFSwas observed in patients having>2.37%CD20+ and>6.05%CD7+
lymphocytes compared to 61.1% LFS in patients having≤2.37%CD20 and≤6.05%CD7 expression (H).
production of immunostimulatory cytokines.9,10 Thus, the collabo-
ration of different types of lymphocyte may confer the capacity
to develop a robust adaptive immune response against autologous
tumour cells.
Our findings, combined with the findings reported by Lustfeld
et al.,4 provide the first information related to the relevance of
the tumour immune contexture in paediatric ALL. An increased fre-
quency of mature immune cell components within the BM tumour
micro-environment is strongly associated with both early treatment
response4 and successful chemotherapeutic treatment. Further, elu-
cidating the relationships between immune infiltrate components at
diagnosis and treatment response may provide a means to enhance
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immediate treatment risk stratification. Of the eight childrenwho died
in this study, three had no clinical high risk features and were treated
according to Regimen A. All three of these children had low CD20 lev-
els at diagnosis, and two of these three also had low CD7 levels. Reli-
able identification of very good risk and very high risk patients at diag-
nosis potentially offers the opportunity to reduce or intensify therapy
from induction onward. Our data clearly define two important patient
sub-groups; firstly, one forwhich the chemotherapeutic treatment reg-
imenwas 100% successful, and secondly, one inwhich patientswere at
significantly increased risk of treatment failure. Notwithstanding the
limitations of this single centre retrospective study of small numbers,
it seems relevant that the tumour immune contexture in paediatric
ALL receives future attention, both to confirm our observations and to
investigate mechanistically the benefit to patients of mature immune
cell BM infiltrate at treatment commencement.
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ALL acute lymphoblastic leukaemia
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REFERENCES
1. Fridman WH, Pages F, Sautes-Fridman C, et al. The immune contex-
ture in human tumours: Impact on clinical outcome. Nat Rev Cancer.
2012;12(4):298–306.
2. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of
immune cells within human colorectal tumors predict clinical outcome.
Science. 2006;313(5795):1960–1964.
3. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prog-
nostic factors of colorectal cancers are associated with the state of the
local immune reaction. J Clin Oncol. 2011;29(6):610–618.
4. Lustfeld I, Altvater B, Ahlmann M, et al. High proportions of CD4+
T cells among residual bone marrow T cells in childhood acute lym-
phoblastic leukemia are associatedwith favorable early responses.Acta
Haematol. 2014;131(1):28–36.
5. Low M, Lee D, McLean C, et al. Detectable CD8 cells correlate with
improved overall survival in adult B lymphoblastic leukaemia patients.
Br J Haematol. 2014;165(6):883–885.
6. Halama N, Michel S, Kloor M, et al. Localization and density of
immune cells in the invasive margin of human colorectal cancer liver
metastases are prognostic for response to chemotherapy. Cancer Res.
2011;71(17):5670–5677.
7. Gilboa E. The makings of a tumor rejection antigen. Immunity.
1999;11(3):263–270.
8. Lanzavecchia A. Antigen-specific interaction between T-cells and
B-cells.Nature. 1985;314(6011):537–539.
9. Hodgkin PD, Rush J, Gett AV, et al. The logic of intercellular communi-
cation in the immune system. Immunol Cell Biol. 1998;76(5):448–453.
10. Clark EA, Ledbetter JA. How B-cells and T-cells talk to each other.
Nature. 1994;367(6462):425–428.
